Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Pulikottil-Jacob

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 8, 2020
Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry studyRichard S Nicholas, Martin L Heaven, Rodden M Middleton, et al.
Plos One|November 2, 2016
Has Metal-On-Metal Resurfacing Been a Cost-Effective Intervention for Health Care Providers?-A Registry Based StudyRuth Pulikottil-Jacob, Martin Connock, Ngianga-Bakwin Kandala, et al.
Orphanet Journal of Rare Diseases|April 17, 2020
Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseasesNicole Lyn, Ruth Pulikottil-Jacob, Camille Rochmann, et al.
Orphanet Journal of Rare Diseases|November 21, 2025
Burden of caregiving of individuals with GM1 and GM2 gangliosidoses in the United States: a qualitative studyMaria Belen Rodriguez, Ruth Pulikottil-Jacob, Karli Heuer, et al.
Advances in Therapy|May 27, 2024
Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP)Raphael Schiffmann, Eugen Mengel, Mary Wallace, et al.
Age and Ageing|February 10, 2017
The Community In-reach Rehabilitation and Care Transition (CIRACT) clinical and cost-effectiveness randomisation controlled trial in older people admitted to hospital as an acute medical emergencyOpinder Sahota, Ruth Pulikottil-Jacob, Fiona Marshall, et al.
Orphanet Journal of Rare Diseases|April 13, 2024
A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in GermanyEugen Mengel, Nicole Muschol, Natalie Weinhold, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 27, 2024
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)Louis S Matza, Katie D Stewart, Marie Fournier, et al.
European Journal of Medical Genetics|June 9, 2024
Natural history of acid sphingomyelinase deficiency among European patients during childhood and adolescence: A retrospective observational studyEugen Mengel, Maurizio Scarpa, Nathalie Guffon, et al.
Journal of Neuromuscular Diseases|May 21, 2025
Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe diseaseKenneth I Berger, Cristina Ivanescu, Jérôme Msihid, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 8, 2020
Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry studyRichard S Nicholas, Martin L Heaven, Rodden M Middleton, et al.
Plos One|November 2, 2016
Has Metal-On-Metal Resurfacing Been a Cost-Effective Intervention for Health Care Providers?-A Registry Based StudyRuth Pulikottil-Jacob, Martin Connock, Ngianga-Bakwin Kandala, et al.
Orphanet Journal of Rare Diseases|April 17, 2020
Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseasesNicole Lyn, Ruth Pulikottil-Jacob, Camille Rochmann, et al.
Orphanet Journal of Rare Diseases|November 21, 2025
Burden of caregiving of individuals with GM1 and GM2 gangliosidoses in the United States: a qualitative studyMaria Belen Rodriguez, Ruth Pulikottil-Jacob, Karli Heuer, et al.
Advances in Therapy|May 27, 2024
Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP)Raphael Schiffmann, Eugen Mengel, Mary Wallace, et al.
Age and Ageing|February 10, 2017
The Community In-reach Rehabilitation and Care Transition (CIRACT) clinical and cost-effectiveness randomisation controlled trial in older people admitted to hospital as an acute medical emergencyOpinder Sahota, Ruth Pulikottil-Jacob, Fiona Marshall, et al.
Orphanet Journal of Rare Diseases|April 13, 2024
A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in GermanyEugen Mengel, Nicole Muschol, Natalie Weinhold, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 27, 2024
Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD)Louis S Matza, Katie D Stewart, Marie Fournier, et al.
European Journal of Medical Genetics|June 9, 2024
Natural history of acid sphingomyelinase deficiency among European patients during childhood and adolescence: A retrospective observational studyEugen Mengel, Maurizio Scarpa, Nathalie Guffon, et al.
Journal of Neuromuscular Diseases|May 21, 2025
Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe diseaseKenneth I Berger, Cristina Ivanescu, Jérôme Msihid, et al.
Pageof 4